Oncolytics Biotech, Inc.

Twitter LinkedIn
  • Home
  • About
    • Our Company
    • Management Team
    • Board of Directors
  • Technology
    • What is Pelareorep?
    • What Does Pelareorep Do?
    • Delivery
    • Intellectual Property
    • Posters & Publications
    • Manufacturing
  • Clinical Trials
    • Clinical Development Plan
    • Collaborators
    • Pipeline
  • Media
    • Press Releases
    • Insights
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Filings & Financials
    • Corporate Governance
    • FAQs
    • Email Alerts
    • IR Contacts
  • Contact
  • Careers

News

Media

Media

  • Press Releases
  • Insights
May 29, 2007

Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Paclitaxel and Carboplatin Trial

May 14, 2007

U.S. NCI Files for Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)

May 2, 2007

Oncolytics Biotech Inc. Announces Details of 2007 Annual Shareholder Meeting

Apr 30, 2007

Oncolytics Biotech Inc. Successfully Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R)

Apr 27, 2007

Oncolytics Biotech Inc. Announces 2007 First Quarter Results

Apr 17, 2007

Oncolytics Biotech Inc. Research Collaborators Demonstrate Reovirus/Gemcitabine Combination Has Synergistic Effect Against Human Colon Cancer Cell Lines

Apr 11, 2007

Oncolytics Biotech Inc. Proceeds to Initiate U.S. Phase II Sarcoma Clinical Trial

Apr 3, 2007

Oncolytics Biotech Inc. Announces Issuance of 20th U.S. Patent

Mar 21, 2007

Oncolytics Biotech Inc. Announces Closing of Over-Allotment Option

Mar 19, 2007

Oncolytics Biotech Inc. Research Collaborators Present Combination Reovirus and Cyclophosphamide Treatment Results at International Oncolytic Virus Conference

    • 1...
    • 49
    • 50
    • 51
    • 52
    • 53
    • 54
    • 55
    • 56
    • 57
    • 58
    © 2022 Oncolytics Biotech, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap